Program
All in-person attendees will be required to show proof of vaccination against COVID-19 in order to enter the Salk Institute. Proof includes your vaccination card or a photocopy.
The 17th Annual Peptide Therapeutics Symposium will be held in a hybrid format on October 20th and 21st, 2022. An interactive poster session will be held each day. Registrants will have access to recorded presentations following the close of the meeting.
17th Annual Peptide Therapeutics Symposium
October 20 – 21, 2022
Hybrid Meeting
|
| Preliminary Program |
| Thursday, October 20, 2022 |
| 7:00 a.m. – 4:15 p.m. | Registration Check-in
Fritz B. Burns Reception Center, Lower Level |
| 8:00 a.m. – 4:45 p.m. | 17th Annual Peptide Therapeutics Symposium
Conrad T. Prebys Auditorium |
| 8:00 a.m. – 8:15 a.m. | Opening Remarks |
| 8:15 a.m. – 10:15 a.m. | Plenary Lectures |
| 8:15 a.m. – 9:15 a.m. | The Next Generation of RaPID System
Hiroaki Suga, Ph.D.
Professor, The University of Tokyo |
| 9:15 a.m. – 10:15 a.m. | Ionic Liquids for Delivery of Biologics
Samir Mitragotri, Ph.D.
Professor, Harvard University |
| 10:15 a.m. – 10:45 a.m. | Beverage Break
|
| 10:45 a.m. – 12:30 p.m. | Session I
|
| 10:45 a.m. – 11:15 a.m. | Engineering Long-acting Relaxin ThP - AZD3427
Monika Papworth, Ph.D.
Biologics Engineering
AstraZeneca R&D, Cambridge UK |
| 11:15 a.m. – 11:45 a.m. | Discovery of AMG133, a Novel GIPR Antagonist Antibody/GLP-1 Peptide Bispecific Conjugate for the Treatment of Obesity
Yuan Cheng, Ph.D.
Senior Principal Scientist
Amgen Inc |
| 11:45 a.m. – 12:30 p.m. | Poster Presentations
|
| 12:30 p.m. – 1:30 p.m. | Lunch Break |
| 1:30 p.m. – 3:00 p.m. | Session II
Richard DiMarchi Celebration
Moderator:
Soumitra Ghosh, Ph.D.
President, Doon Associates LLC |
| 1:30 p.m. – 1:45 p.m. | Introduction
Soumitra Ghosh, Ph.D.
President, Doon Associates LLC |
| 1:45 p.m. – 2:15 p.m. | Chemical Optimization of the Pancreatic Glycemic Hormones
John P. Mayer, Ph.D.
Research Scientist Dept. of Molecular, Cellular and Developmental Biology
University of Colorado, Boulder, CO |
| 2:15 p.m. – 2:45 p.m. | From Serendipity to Rational Design: Multimodality Therapeutics for Multimorbidity Diseases
Brian Finan, Ph.D.
Vice President of Obesity Research, Novo Nordisk |
| 2:45 p.m. – 3:15 p.m. | A Hundred Years Ago Today the Band Began to Play
Richard DiMarchi, Ph.D.
Distinguished Professor of Chemistry, Gill Chair in Biomolecular Sciences, Department of Chemistry, Indiana University |
3:15 p.m. – 3:45 p.m.
| Beverage Break |
3:45 p.m. – 4:45 p.m.
| Session III
Poster Presentation
|
4:45 p.m. – 6:30 p.m.
| Opening Reception
|
| Friday, October 21, 2022 |
| 7:00 a.m. – 4:15 p.m. | Registration Check-in
Fritz B. Burns Reception Center, Lower Level |
| 8:00 a.m. – 4:45 p.m. | 17th Annual Peptide Therapeutics Symposium
Conrad T. Prebys Auditorium |
| 8:00 a.m. – 8:15 a.m. | Welcoming Remarks |
| 8:15 a.m. – 10:15 a.m. | Plenary Lectures
|
| 8:15 a.m. – 9:15 a.m. | Discovery and Characterization of Novel Peptides and Small Proteins
Alan Saghatelian, Ph.D.
The Salk Institute for Biological Studies |
| 9:15 a.m. – 10:15 a.m | Exploration of Improved MC4R Agonist and Novel MC3R Antagonist Peptides for the Treatment of Obesity
Roger D. Cone, Ph.D.
Director, Life Sciences Institute, University of Michigan
|
| 10:15 a.m. – 10:45 a.m. | Beverage Break |
| 10:45 a.m. – 12:30 p.m. | Session IV |
| 10:45 a.m. – 11:15 a.m. | Development of Differentiated Peptide Therapeutic Products Using an Innovative Formulation Technology
Jan Jezek, Ph.D.
Chief Scientific Officer
Arecor |
| 11:15 a.m. – 11:45 a.m. | A New Approach to Cancer Therapy with Documented Clinical Effects
Catharina Svanborg, M.D., Ph.D.
Professor of Clinical Immunology at Lund University (emeritus) |
| 11:45 a.m. – 12:30 p.m. | Poster Presentations
|
| 12:30 p.m. – 1:30 p.m. | Lunch Break |
| 1:30 p.m. – 3:15 p.m. | Session V
|
| 1:30 p.m. – 2:00 p.m. | Invention of Oral PCSK9 Inhibitor from mRNA Display Selection
Abbas M. Walji, Ph.D.
Director, Discovery Chemistry
Merck & Co. Inc. |
| 2:00 p.m. – 2:30 p.m. | Oral Inhibitors of the SARS-CoV-2 Main Protease for the Treatment of COVID-19
Dafydd Owen, Ph.D.
Senior Scientific Director, Medicinal Chemistry
Pfizer Medicine Design, Cambridge, MA, USA |
| 2:30 p.m. – 3:00 p.m. | Poster Presentations |
| 3:00 p.m. – 3:30 p.m. | Beverage Break |
| 3:30 p.m. – 4:45 p.m. | Session VI
|
| 3:30 p.m. – 4:00 p.m. | GLP-1 Receptor Bias Agonists: The Long and Short of It.
Patricia McDonald, Ph.D.
Associate Professor, Moffitt Cancer Center & Research Institute |
| 4:00 p.m. – 4:30 p.m. | CryoEM After the Resolution Revolution: Achievements, Developments and Challenges
Anette Schneemann, Ph.D.
Senior Staff Scientist
Scripps Research |
| 4:30 p.m. – 4:45 p.m. | Closing Remarks
|
| 4:45 p.m. – 6:00 p.m. | Closing Reception |
|
Peptide Therapeutic Foundation
|
